-
Product Insights
MC#1 Mine
The MC#1 Mine is a coal mine in United States. It is currently in operation. Empower your strategies with our MC#1 Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain vital...
-
Product Insights
MC Mining Complex
The MC Mining Complex is a coal mine in United States. It is currently in operation. Empower your strategies with our MC Mining Complex report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy...
-
Product Insights
Wesley MC – 833 North Vassar Avenue Rehabilitation Hospital – Kansas
Equip yourself with the essential tools needed to make informed and profitable decisions with our Wesley MC – 833 North Vassar Avenue Rehabilitation Hospital – Kansas report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MC-232 in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MC-232 in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MC-232 in Hidradenitis Suppurativa Drug Details: MC2-32 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MC-225 in Uremic (Renal) Pruritus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MC-225 in Uremic (Renal) Pruritus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MC-225 in Uremic (Renal) Pruritus Drug Details: MC-225 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MC-001 in Spinal Cord Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MC-001 in Spinal Cord Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MC-001 in Spinal Cord InjuryDrug Details:MC-001 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MC-232 in Plaque Psoriasis (Psoriasis Vulgaris)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MC-232 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: MC-232 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venadaparib in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venadaparib in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venadaparib in Gastric Cancer Drug Details: IDX-1197 (NOV1401) is under development for...
-
Product Insights
Ocular Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ocular Melanoma - Drugs In Development, 2023’, provides an overview of the Ocular Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...